CB2 Insights Announces Results of Special Shareholders Meeting and Schedule for Q3 2020 Earnings Call
25 Novembro 2020 - 6:32PM
CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“
CB2” or
the “
Company”), one of the largest multi-specialty
healthcare systems in the United States, is pleased to announce
that it has received majority vote for all 3 resolutions proposed
in its special meeting of the shareholders held November 23, 2020.
The table below shows the percentage in favor for each of the 3
resolutions.
Resolution |
Votes in Favour |
Votes Against |
Resolution to approve the delisting from the Canadian Securities
Exchange and the relisting on the TSX Venture Exchange |
99.99% |
0.01% |
Resolution to approve the changing of the name of the corporation
to Skylight Health Group Inc. |
99.99% |
0.01% |
Resolution to approve a new stock option plan |
99.99% |
0.01% |
The Company is currently in application process with the TSX
Venture Exchange. Further, the Company expects to launch with a new
brand reveal on Monday November 30th, 2020 in coordination with the
change of its name to Skylight Health Group and its trading symbol
to “SHG” on the Canadian Securities Exchange.
The Company will be hosting its Q3 2020 earnings call on
Tuesday, December 1st, 2020 at 9:00 a.m. Eastern Daylight Time
(EDT).
CB2 will issue a press release and file its interim financial
statements and interim Quarterly Management Discussion and Analysis
(“MD&A”) for the quarter ended September 30, 2020 (the “Q3 2020
Filings”) after the close of markets on November 30th, 2020.
Conference
Call
Details:
Date: |
Tuesday, December 1st, 2020 |
Time: |
9:00 a.m. (EDT) |
US/Canada Toll Free Dial
In: |
1-800-319-4610 |
Toronto Local Dial In: |
1-416-915-3239 |
International Dial In: |
1-604-638-5340 |
Call Name: |
CB2 Insights Earnings
Call |
A replay of the earnings call will be available on the company’s
website 24 hours after the call takes place.
Submitting Questions:
Those interested in submitting questions for the earnings call
can do so by emailing investors@cb2inisghts.com prior to the start
of the call. CB2 Insights will attempt to answer all questions
submitted, however some questions may not be answered during the
call due to time constraints.
The Company looks forward to providing additional discussion on
its Q3 2020 Filings, as well as providing an update on the business
and preliminary expectations for Q4 2020. Further, the Company will
update shareholders on its future outlook and plans for growth in
the coming quarters.
About CB2 Insights
CB2 Insights Inc. (CSE:CBII OTCQB:CBIIF) is a healthcare
services and technology company, working to positively impact
patient health outcomes. The Company operates a US multi-state
health network that comprises of physical multi-disciplinary
medical clinics providing a range of services from primary care,
sub-specialty, allied health and laboratory/diagnostic testing. The
Company owns and operates a proprietary electronic health record
system that supports the delivery of care to patients via
telemedicine and other remote monitoring system integrations.
healthcare services. With a patient roster of over 120,000
patients, the Company’s operations spread across 14 states and
continues to expand in services and locations both organically and
by way of strategic acquisitions.
The Company primarily operates a traditional insurable
fee-for-service model contracting with Medicare, Medicaid and other
Commercial Payors. The Company also offers a disruptive
subscription-based telemedicine service for the un/under-insured
population who have limited access to urgent care due to cost.
For more information please visit www.cb2insights.com or
contact:
Investor RelationsJonathan L. Robinson CFAOak Hill
Financialjrobinson@oakhillfinancial.ca416-669-1001
Forward Looking Statements
Statements in this news release that are
forward-looking statements are subject to various risks and
uncertainties concerning the specific factors disclosed here and
elsewhere in CB2’s filings with Canadian securities regulators.
When used in this news release, words such as "will, could, plan,
estimate, expect, intend, may, potential, believe, should," and
similar expressions, are forward-looking statements.
Forward-looking statements may include, without
limitation, statements regarding the Company’s unaudited financial
results and projected growth.
Although CB2 has attempted to identify important
factors that could cause actual results, performance or
achievements to differ materially from those contained in the
forward-looking statements, there can be other factors that cause
results, performance or achievements not to be as anticipated,
estimated or intended, including, but not limited to: general
business and economic conditions; the potential impact of COVID-19;
dependence on obtaining regulatory approvals; limitations on
insurance coverage; the ability to locate and complete acquisitions
with appropriate targets; reliance on management; the ability to
attract and retain qualified staff; requirements for additional
financing; competition; and; regulatory or political change.
There can be no assurance that such information will prove to be
accurate or that management's expectations or estimates of future
developments, circumstances or results will materialize. As a
result of these risks and uncertainties, the results or events
predicted in these forward-looking statements may differ materially
from actual results or events.
Accordingly, readers should not place undue reliance on
forward-looking statements. The forward-looking statements in this
news release are made as of the date of this release. CB2 disclaims
any intention or obligation to update or revise such information,
except as required by applicable law, and CB2 does not assume any
liability for disclosure relating to any other company mentioned
herein.
No securities regulator or exchange has reviewed,
approved, disapproved, or accepts responsibility for the content of
this news release.
CB2 Insights (CSE:CBII)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
CB2 Insights (CSE:CBII)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025